112 related articles for article (PubMed ID: 15816354)
1. Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer.
Green AR; Styles JA; Parrott EL; Gray D; Edwards RE; Smith AG; Gant TW; Greaves P; Al-Azzawi F; White IN
Exp Toxicol Pathol; 2005 Mar; 56(4-5):255-63. PubMed ID: 15816354
[TBL] [Abstract][Full Text] [Related]
2. Adenomyosis--a result of disordered stromal differentiation.
Parrott E; Butterworth M; Green A; White IN; Greaves P
Am J Pathol; 2001 Aug; 159(2):623-30. PubMed ID: 11485920
[TBL] [Abstract][Full Text] [Related]
3. [Effects of raloxifene on other organs without bone: uterus].
Nozaki M
Clin Calcium; 2004 Oct; 14(10):55-60. PubMed ID: 15577132
[TBL] [Abstract][Full Text] [Related]
4. Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen.
Pole JC; Gold LI; Orton T; Huby R; Carmichael PL
Toxicology; 2005 Jan; 206(1):91-109. PubMed ID: 15590111
[TBL] [Abstract][Full Text] [Related]
5. Co-occurrence of atypical endometriosis, subserous uterine leiomyomata, sactosalpinx, serous cystadenoma and bilateral hemorrhagic corpora lutea in a perimenopausal adipose patient taking tamoxifen (20 mg/day) for invasive lobular breast cancer.
Ebert AD; Rosenow G; David M; Mechsner S; Magalov IS; Papadopoulos T
Gynecol Obstet Invest; 2008; 66(3):209-13. PubMed ID: 18645252
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of oestradiol, tamoxifen and raloxifene on nerve growth factor-alpha expression in specific neonatal mouse uterine cell types using laser capture microdissection.
Green AR; Edwards RE; Greaves P; White IN
J Mol Endocrinol; 2003 Feb; 30(1):1-11. PubMed ID: 12580757
[TBL] [Abstract][Full Text] [Related]
7. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
8. Analysis of gene expression profiles in the offspring of rats following maternal exposure to xenoestrogens.
Dang VH; Choi KC; Hyun SH; Jeung EB
Reprod Toxicol; 2007 Jan; 23(1):42-54. PubMed ID: 17011747
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen associated uterine pathology in breast cancer patients with abnormal bleeding.
Fotiou S; Tserkezoglou A; Hadjieleftheriou G; Apostolikas N; Karydas I; Stravolemos K
Anticancer Res; 1998; 18(1B):625-9. PubMed ID: 9584044
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Oxymetholone (CAS NO. 434-07-1) in F344/N Rats and Toxicology Studies of Oxymetholone in B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Aug; 485():1-233. PubMed ID: 12571678
[TBL] [Abstract][Full Text] [Related]
11. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
12. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
Deligdisch L; Kalir T; Cohen CJ; de Latour M; Le Bouedec G; Penault-Llorca F
Gynecol Oncol; 2000 Aug; 78(2):181-6. PubMed ID: 10926800
[TBL] [Abstract][Full Text] [Related]
13. Alterations in developing rat uterine cell populations after neonatal exposure to estrogens and antiestrogens.
Branham WS; Zehr DR; Chen JJ; Sheehan DM
Teratology; 1988 Sep; 38(3):271-9. PubMed ID: 3227494
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of human adenomyosis.
Hever A; Roth RB; Hevezi PA; Lee J; Willhite D; White EC; Marin EM; Herrera R; Acosta HM; Acosta AJ; Zlotnik A
Mol Hum Reprod; 2006 Dec; 12(12):737-48. PubMed ID: 17020905
[TBL] [Abstract][Full Text] [Related]
15. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.
Hui AM; Zhang W; Chen W; Xi D; Purow B; Friedman GC; Fine HA
Cancer Res; 2004 Dec; 64(24):9115-23. PubMed ID: 15604281
[TBL] [Abstract][Full Text] [Related]
16. High frequency of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen.
Cohen I; Beyth Y; Shapira J; Tepper R; Fishman A; Cordoba M; Bernheim J; Yigael D; Altaras MM
Gynecol Obstet Invest; 1997; 44(3):200-5. PubMed ID: 9359649
[TBL] [Abstract][Full Text] [Related]
17. Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis.
Newbold RR; Bullock BC; McLachlan JA
Cancer Res; 1990 Dec; 50(23):7677-81. PubMed ID: 2174729
[TBL] [Abstract][Full Text] [Related]
18. Histopathology and histomorphometry of the urogenital tract in 15-month old male and female rats treated neonatally with SERMs and estrogens.
Karlsson S
Exp Toxicol Pathol; 2006 Aug; 58(1):1-12. PubMed ID: 16709447
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of Talc (CAS No. 14807-96-6)(Non-Asbestiform) in F344/N Rats and B6C3F1 Mice (Inhalation Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 421():1-287. PubMed ID: 12616290
[TBL] [Abstract][Full Text] [Related]
20. Neonatal administration of tamoxifen causes disruption of myometrial development but not adenomyosis in the C57/BL6J mouse.
Mehasseb MK; Bell SC; Habiba MA
Reproduction; 2010 Jun; 139(6):1067-75. PubMed ID: 20368191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]